Dbv technologies undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. Fr0010417345 the following is courtesy of corporate press release distributed by globe newswire bagneux, france, july 20, 2015 dbv technologies the company euronext. Dbv technologies sa announces pricing of global offering torreya. Dbv technologies to attend upcoming investor conferences. May 03, 2012 the roadshow site also hosts the prospectus for investors embedded below. A dbv technologies announces results of its 2020 ordinary and extraordinary general meeting. Dbv technologies reports full year 2015 financial results. Dbv technologies sa is a biopharmaceutical company. Dbv technologies is known for developing viaskin technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Dbv technologies reports march 31, 2020 cash position finance. Dbv technologies therapies are investigational and not fda approved. Viaskin peanut receives fda fast track designation download pdf 18 kb 2012.
Announces pricing of global offering bagneux, france october 22, 2014 dbv technologies euronext. Oct 20, 2017 dbv technologies announces topline results of phase iii clinical trial in peanutallergic patients four to 11 years of age. Nasdaq gs stock quote dbv technologies sa bloomberg. Dbv technologies to attend upcoming investor conferences twitter. Fr0010417345, a clinicalstage specialty biopharmaceutical company announced today that it intends to offer and sell, subject to market and. Stock information investor faqs corporate governance. Et on seeking alpha dbv technologies expands leadership team. Dbvt dbv technologies sa summary, stock quote and news. Successful initial public offering ipo for dbv technologies download pdf 401 kb 2012. Dbv technologies reports september 30, 2017 cash position.
Dbv technologies and aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist. Dbv technologies forms magic partnership with nestle. Dbv technologies reports march 31, 2020 cash position download pdf kb 2020. Bagneux, france october 22, 2014 dbv technologies euronext. Dbv technologies announces closing of global offering and. Persons who access the electronic version of this prospectus should ensure that they download and read the entire prospectus. They are a clinicalstage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called viaskin. Please download the free adobe acrobat reader to view these documents. Dbvt today announced its cash and cash equivalents as of. Dbv technologies announces results of its 2020 ordinary and extraordinary general meeting download pdf 201 kb 2020. Dbv technologies provides update on regulatory progress for viaskin peanut. About dbv technologies dbv technologies is developing viaskin, a proprietary technology platform with broad potential applications in immunotherapy. Free forex prices, toplists, indices and lots more.
This preliminary prospectus supplement and the accompanying prospectus are not an. Dbvt, a clinicalstage biopharmaceutical company, today announced the settlement and delivery on. While its always nice to make more money than you expected, a company with predictable free cash flow is stable and good. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. Dbv technologies dbvt says phase iii trial of viaskin peanut in patients four to 11 years of age did not reach primary endpoint article related press releases 1 related articles 1 stock.
Biopharmaceutical food allergy treatments dbv technologies. Jun 07, 2016 dbv technologies forms magic partnership with nestle. Copies of the prospectus approved by the amf march 12, 2012 under the. This prospectus is not an offer to sell these securities and we are not soliciting offers to buy these. The prospectus include essentially the same information as facebooks s1 filing to ipo, but with more polished. Edt after announcing that its peanut allergy treatment, viaskin peanut, failed albeit not by much a phase 3 trial. Dbvt 12 month eps 12 month eps the style scores are a complementary set of indicators to use alongside the zacks rank. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Viaskin peanut clinical development has received fast track designation from the us. Dbv technologies dbvt says phase iii trial of viaskin.
When available, copies of the final prospectus relating to the offering may be obtained from. The free cash flow jitter of a stock measures how much the companys free cash flow varies from its historical trend, on average. Dbv technologies down 5% on pricing shares offering apr. A dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports december 31, 2019. Viaskin peanut clinical development has received fast track designation from the us food and drug administration.
Dbvt stock, price quote and chart, trading and investing tools. En paris stock quote dbv technologies sa bloomberg. A company with wild swings in its free cash flow warrants further research. Dbv technologies sa is a publicly owned french biopharmaceutical firm headquartered in bagneux, france.
Dbv technologies announces topline results of phase iii. When available, copies of the final prospectus relating to. Dbv technologies sa is a biotechnology company that provides therapy for food and pediatric allergy patients. This is the initial public offering of our american depositary shares, or adss. Dbv technologies announces results of its 2020 ordinary and extraordinary general meeting. Announces proposed global offering bagneux, france october 20, 2014 dbv technologies euronext. Its lead product candidate is viaskin peanut, an immunotherapy product, which has completed phase iii clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Dbvt ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Why dbv technologies sa plummeted and aimmune therapeutics. Dbv technologies focuses on the development of innovative products for the diagnosis and treatment of food allergies. Oct 31, 2017 dbv technologies reports september 30, 2017 cash position. Dbvt stock quote, history, news and other vital information to help you with your stock trading and investing. Nasdaq gs including stock price, stock chart, company news, key statistics, fundamentals and company profile. Dbv technologies announces fda acceptance of bla filing for viaskin peanut for the treatment of peanut allergy. Dbv technologies investors go into shock with filing withdrawal. Dbv technologies is developing viaskin, an investigational proprietary technology platform with broad potential applications in. Technology and life sciences ipo survey 2015, first half. This prospectus is also available in electronic form to australian residents on costas offer website. Successful initial public offering ipo for dbv technologies. Dbvt has 96 institutional owners and shareholders that have filed dg or f forms with the securities exchange commission sec. Dbv technologies announces filing of 2019 universal registration.
Dbv technologies decision to pull its viaskin peanut filing leaves the. Dbv technologies archives isin international securities. These institutions hold a total of 44,251,730 shares. Dbv technologies will host a conference call today, october 20, 2017, at 5. Dbvt today announced topline results from the pepites peanut epit efficacy and safety phase iii trial evaluating the safety and efficacy of viaskin peanut in children. Dbv technologies is a global biopharmaceutical company thats pioneering investigational epicutaneous immunotherapy epit to potentially treat millions of people suffering from life. Get breaking news and analysis on dbv technologies s. Dbv technologies announces full exercise of underwriters option. Successful initial public offering ipo for dbv technologies on the. Dbvt stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on. Stock quotes euronext amsterdam realtime stock prices aex, amx, ascx.
Fr0010417345, a clinicalstage specialty biopharmaceutical company announced today the pricing of its global offering of. The prospectus is also available on the websites of dbv technologies. Monthly information regarding the total number of voting rights and total number of shares of th. Dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports september 30, 2019 cash position. Largest shareholders include baker brothers advisors lp, boxer capital, llc, deerfield.
110 1493 622 757 245 341 1085 282 1474 1578 1074 17 1353 1023 1368 625 1060 958 794 212 734 1560 1035 217 486 55 1480 998 919 740